Literature DB >> 22578612

Ovarian activity reversibility after the use of deslorelin acetate as a short-term contraceptive in domestic queens.

C L Ackermann1, R Volpato, F C Destro, E Trevisol, N Ruas Sousa, C R F Guaitolini, A A P Derussi, T S Rascado, M D Lopes.   

Abstract

The objective was to evaluate ovarian activity reversibility in domestic queens after short-term contraceptive treatment with deslorelin acetate. Ten mature queens were used. In all queens, the estrous cycle was evaluated every 72 h by vaginal cytology (VC) and behavior assessments. When queens had VC characteristic of interestrus or diestrus, one deslorelin acetate implant (4.7 mg) was placed in the subcutaneous tissue of the interscapular region (day of insertion = Day 0). Thereafter, VC was performed every 48 h and on Day 90, implants were removed. At Day 100, estrus and ovulation were induced with 100 IU eCG (im), followed by 100 IU hCG (im), 84 h later (Day 103.5). Queens were ovariohysterectomized on Day 106. Corpora lutea (CL) were counted, oviducts were flushed, and oocytes were identified, isolated and stained to assess viability. In all queens, blood samples for plasma progesterone concentrations were collected once a week, from Days -21 to 106. After deslorelin acetate application, four queens had VC and behavior typical of estrus, and one ovulated. Furthermore, ovulation occurred in three queens that did not have VC or behavior consistent with estrus. After the initial ovarian stimulation, all females had anestrous VC during the deslorelin treatment period. Implants were readily removed. Following implant removal, all females responded to treatments to induce estrus and ovulation. There were (mean ± SEM) 13.1 ± 5.5 CL and 8.1 ± 5.5 oocytes per queen; the oocyte recovery rate was 56.8 ± 25.4% and all recovered oocytes were viable. We concluded that deslorelin acetate can be used as a reversible short-term contraceptive in domestic cats, because estrus and ovulation were successfully induced following implant removal.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22578612     DOI: 10.1016/j.theriogenology.2012.03.030

Source DB:  PubMed          Journal:  Theriogenology        ISSN: 0093-691X            Impact factor:   2.740


  5 in total

1.  Clinical use of Anti-Müllerian Hormone to monitor resumption of ovarian activity following removal of a 4.7 mg deslorelin implant in queens.

Authors:  L Ferré-Dolcet; S Ferro; B Contiero; C Fontaine; T Badon; D Gelli; S Romagnoli
Journal:  Vet Res Commun       Date:  2022-03-26       Impact factor: 2.816

2.  Hormonal Suppression in Female Rhesus Macaques (Macaca mulatta) Implanted Subcutaneously with Deslorelin.

Authors:  Kelsey E Carroll; Alexis L Mackiewicz; Amir Ardeshir; Susan A Alber; Kari L Christe
Journal:  J Am Assoc Lab Anim Sci       Date:  2022-05-05       Impact factor: 1.706

3.  Characterization of Ovarian Steroid Patterns in Female African Lions (Panthera leo), and the Effects of Contraception on Reproductive Function.

Authors:  Sarah B Putman; Janine L Brown; Ashley D Franklin; Emily C Schneider; Nicole P Boisseau; Cheryl S Asa; Budhan S Pukazhenthi
Journal:  PLoS One       Date:  2015-10-13       Impact factor: 3.240

4.  Length of efficacy and effect of implant location in adult tom cats treated with a 9.4 mg deslorelin subcutaneous implant.

Authors:  Stefano Romagnoli; Anna Baldan; Silvia Ferro; Camilla Righetti; Ludovico Scenna; Gianfranco Gabai; Tamara Badon; Christelle Fontaine; Antonio Mollo; Calogero Stelletta; Chiara Milani
Journal:  J Feline Med Surg       Date:  2018-07-30       Impact factor: 2.015

Review 5.  Long-term contraception in a small implant: A review of Suprelorin (deslorelin) studies in cats.

Authors:  Christelle Fontaine
Journal:  J Feline Med Surg       Date:  2015-09       Impact factor: 2.015

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.